NCT07426822 2026-02-24
SAFE-CAP
Yale University
Phase 2 Not yet recruiting
Clinical Trials
13 trialsNCT01391962 2026-02-02
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT06865677 2026-01-21
Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT05520723 2025-12-04
PRIMED
MedSIR
Phase 2 Completed
NCT03094052 2025-06-26
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
University of California, San Francisco
Phase 2 Completed
NCT05252988 2025-04-01
DIANER
Spanish Breast Cancer Research Group
Phase 2 Active not recruiting
NCT04172597 2024-03-13
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT04366713 2023-02-10
A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib
Puma Biotechnology, Inc.
Phase 2 Completed
NCT02400476 2022-05-06
An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide
Puma Biotechnology, Inc.
Phase 2 Completed
NCT02441946 2020-06-17
neoMONARCH
Eli Lilly and Company
Phase 2 Completed
NCT03705442 2018-10-15
Probat-tmcc-17
University Hospital Rijeka
Phase 2 Unknown
NCT00401388 2018-03-07
A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas
AEterna Zentaris
Phase 2 Completed
NCT02323516 2015-12-08
ASPIDIA
Centre Francois Baclesse
Phase 2 Withdrawn